Tumor progression, threat to vision and hypothalamic‐pituitary dysfunction in the case of an optic pathway glioma, tumor location, residual disease, age of the patient, and association with neurofibromatosis type 1 (NF1) can influence the decision about particular chemotherapeutic regimens.14 Currently, numerous protocols are available to halt progression or delay the need for potentially damaging radiation treatment. The gene discussed is NF1; the disease is neoplasm.